Oral Cancer Clinical Trial
Official title:
Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University
Background: Due to the complex treatment modalities and long-term side effects, oral cancer
(OC) patients might suffer from psychological and physical distress and be unable to return
to work (RTW).
Purposes: This is a two-phase study. First, the investigator aims to validate a scale about
OC patients' perception of RTW and identify those concerns in RTW. Second, the investigator
aims to (1) develop the contents of a "Personalized Survivorship Care Plan- Oral Cavity
Cancer (PSCP-OC)" and (2) examine the short and long-term effects of PSCP-OC on patients'
physical function (symptoms, muscle strengths, fitness, nutrition status), psychological
distress (depression, fear of cancer recurrence) and RTW.
Method: First phase, the investigator will modify and validate the "Illness Perception
Questionnaire (IPQ)" with adding the head and neck cancer specific items (modified IPQ-mHN)
to assess the barriers of RTW in OC patients. The investigator will recruit 300 subjects in
this phase to test the IPQ-mHN psychometrics. The second and third year will develop and test
the PSCP-OC intervention. Eligible subjects will be (1) newly diagnosed OC patients with
surgery, and (2) who are at work in time of diagnosis. A stratified randomization by cancer
stage would be conducted. Both groups will receive baseline assessment before first
intervention. PSCP-OC is a 6-month intervention which includes two parts: General module and
Personalized module (150 subjects for each group). Ex group will receive the first PSCP-OC
before discharge and 3 times face-to-face PSCP-OP once a month in the first three month after
discharge and 3 times telephone physical-psycho-education interventions in month 4-6. Control
group will receive regular and cancer case manager cares for 6 months. Each group will be
followed for 12 months and assess of their outcomes at 6 time points: baseline
(pre-discharge) and 1, 3, 6, and 12 months after surgery. Outcomes will be evaluated by
physical distress, muscle strength, nutrition status, and length of time of RTW since
completion of last major treatment. Results would be analyzed mainly by GEE. IRB approval
will be received before the RCT.
Expected Outcome: Expecting to develop a scale to identify those barriers preventing OC
patients' RTW and further to test the PSCP. A promising result will further apply into
clinical care to prevent or decrease the potential declined physical and psychological
functions, increase their strength and help them RTW.
Supportive Care has been proved to not only increase patients' life quality but also their
survival time. An influential randomized control study published on the New England Journal
of Medicine (Temel et al., 2010) found that the early palliative (supportive) care could
significantly improve patients' QOL and median survival time (11.6 month vs. 8.9 months) in a
151 metastatic NSCLC patients. This study strongly supports our clinical care needs and
scientific assumption that effective and continuous supportive care is needed in advanced OC
patients.
However, in Taiwan, there is no insurance paying for supportive care in both inpatient and
particularly in OPD (only pay for treatment and physician fee). In order to meet patients'
care need and concerning the reality of our medical payment system, the investigator aims to
develop a systematic well-planed and efficient survivor care plan (SCP), with taking
consideration of OC patients/survivors' personal care needs across different cancer process.
Survivorship Care Plan (SCP) Cancer survivor is defined as "any patient who has been
diagnosed with cancer and continues through their lifespan(NIH, 2014)". One of the most
important reports about survivorship care and content of care has been reported by Institute
of Medicine (IOM, 2006). According to IOM, the essential component of survivorship care
includes "communication and coordination of care, prevention and detection of recurrence,
assessment and management of treatment/disease related distress or late effects. A
well-designed survivor care plan (SCP) has been viewed as an important communication tool to
improve transitions of care for cancer patients. Increasing attentions and reports have been
found about the values of SCP from Office of Cancer Survivorship, and American Society of
Clinical oncology (Mayer, 2014) and strongly suggest to use SCP in clinical cancer practice
to increase the care quality and long-term cancer survivors' quality of life.
There are various models of SCP, in general, the primary care physician model or nurse-led
model are generally being recognized for effective detecting patients' distress and
recurrences, effective coordination and communication, and taking SCP as standard cancer
care. In Taiwan, the investigator takes a large number of advanced OC patients, it is
important to integrate the SCP but also need to concern about the limited time in busy OPD
clinics and patients' differences because of various physical or psychological conditions and
needs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |